CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has...
Industry: Biotechnology
Sector: Healthcare
Phone: 360 980 8524
Fax: 360 799 5954
Address:
1111 Main Street, Suite 660, Vancouver, United States
